Status | Study |
RECRUITING |
Study Name: Spesolimab in Pyoderma Gangrenosum Condition: Pyoderma Gangrenosum Date: 2023-10-16 Interventions: 900 mg of spesolimab intravenously (IV) administered at Weeks 0, 3, 6, 9, 12 and 15. |
RECRUITING |
Study Name: Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum Condition: Pyoderma Gangrenosum Date: 2023-06-29 Interventions: vilobelimab infusion |
NOT_YET_RECRUITING |
Study Name: Deucravacitinib in PG Condition: Pyoderma Gangrenosum Date: 2023-03-20 Interventions: 6 mg tablet |
RECRUITING |
Study Name: Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) Condition: Pyoderma Gangrenosum Date: 2021-05-17 Interventions: Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks. |
Recruiting |
Study Name: An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Condition: Pyoderma Gangrenosum Date: 2017-04-27 Interventions: Biological: Ixekizumab Injection Other Name: Taltz |
Not yet recruiting |
Study Name: Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum Condition: Pyoderma Gangrenosum Date: 2017-02-17 Interventions: Drug: APD334 Other Name: Etrasimod |
Recruiting |
Study Name: Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum Condition: Pyoderma Gangrenosum Date: 2016-03-28 Interventions: Drug: Secukinumab |
Terminated |
Study Name: An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Condition: Pyoderma Gangrenosum Date: 2014-12-22 Interventions: Drug: gevokizumab Drug: Placebo |
Terminated |
Study Name: A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum Condition: Pyoderma Gangrenosum Date: 2014-12-08 Interventions: Drug: gevokizumab |
Completed |
Study Name: A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Condition: Pyoderma Gangrenosum Date: 2013-10-15 Interventions: Biological: Xilonix IV |